Will Portola’s Betrixaban Data Pass Muster With FDA?
This article was originally published in The Pink Sheet Daily
Executive Summary
Portola says that it does not expect it will need to do a second Phase III study to get FDA approval for betrixaban, after missing major endpoint in APEX, but analysts have doubts.
You may also be interested in...
Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
The latest drug development news and highlights from our FDA Performance Tracker.
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
The latest drug development news and highlights from our FDA Performance Tracker.